Notably, Galunisertib monotherapy showed no significant effect on cell viability, whereas its combination with Gemcitabine led to a synergistic response, specifically in /CD90+ cells, underscoring the value of combinatorial approaches in overcoming drug resistance in aggressive iCCA. This evidence concerns the gene THY1 and infantile convulsions and choreoathetosis.